Name

Acute myeloid leukemia with maturation

ICD-O-1 Morphology

9861/3: Acute myeloid leukemia, NOS
Effective 1978 - 1991

ICD-O-2 Morphology

9865/3: FAB M2, NOS; Acute myelocytic leukemia with maturation
Effective 1995 - 2000

ICD-O-3 Morphology

9874/3: Acute myeloid leukemia with maturation
Effective 2001 and later

Reportable

for cases diagnosed 1978 - 1991, 1995 and later

Primary Site(s)

C421
Primary site must be bone marrow (C421)

Abstractor Notes

The provisional diagnosis during workup may include RA with excess blasts, AML without maturation, AML with maturation, and acute myelomonocytic leukemia.

The immunophenotyping information listed below is useful only because it shows those factors that are positive for all myeloid leukemias. The bone marrow only identifies a myeloid neoplasm. Neither the bone marrow biopsy nor the immunophenotyping provide a definitive diagnosis of AML with maturation.

If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.

Grade

Not Applicable

Module Rule

See abstractor notes

Alternate Names

Acute myeloid leukemia, M2
AML with maturation
FAB M2, NOS

Definition

Acute myeloid leukemia (AML) with maturation is characterized by the presence of greater than or equal to 20% blasts in the bone marrow or peripheral blood and evidence of maturation (with greater than or equal to 10% of maturing cells of granulocytic lineage) in the bone marrow; cells of monocyte lineage constitute < 20% of bone marrow cells.

Definitive Diagnostic Methods

Clinical diagnosis
Immunophenotyping

Genetics Data

None

Immunophenotyping

CD7+ (expression/positive)
CD11b+ (expression/positive)
CD13+ (expression/positive)
CD14- (no expression/negative) absent
CD15+ (expression/positive)
CD33+ (expression/positive)
CD34+ (expression/positive)
CD36- (no expression/negative) absent
CD64- (no expression/negative) absent
CD65+ (expression/positive)
HLA-DR+ (expression/positive)
KIT (CD117)+ (expression/positive)

Treatments

Chemotherapy
Hematologic Transplant and/or Endocrine Procedures

Transformations to

None

Corresponding ICD-9 Codes

205.0 Acute myeloid leukemia

Corresponding ICD-10 Codes

C92.0 Acute myeloid leukemia

Corresponding ICD-10-CM Codes (U.S. only)

C92.0 Acute myeloblastic leukemia (effective October 01, 2015)

Signs and Symptoms

Anemia
Easy bruising or bleeding
Fatigue
Fever
Neutropenia
Petechiae
Shortness of breath
Thrombocytopenia
Variable white blood count
Weakness
Weight loss or loss of appetite

Diagnostic Exams

CT (CAT) scan
Cytogenetic analysis
Immunophenotyping
Lumbar puncture
Peripheral blood smear
Physical exam and history
Reverse transcription-polymerase chain reaction test (RT-PCR)

Progression and Transformation

None

Epidemiology and Mortality

Age: all age groups with 20% less than 25 years and 40% greater than 60
Incidence: 10% of all AML cases

Sources

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 158-159

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577

National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Glossary